[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 39 of about 39
1. Katai M, Sakurai A, Inaba H, Ikeo Y, Yamauchi K, Hashizume K: Octreotide as a rapid and effective painkiller for metastatic carcinoid tumor. Endocr J; 2005 Apr;52(2):277-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Octreotide as a rapid and effective painkiller for metastatic carcinoid tumor.
  • Octreotide is one of the somatostatin analogue used for the treatment of endocrine tumors principally to suppress hormone secretion and to inhibit tumor growth.
  • We experienced a case with multiple endocrine neoplasia type 1 who small amount of octreotide dramatically relieved the lumber pain caused by metastatic bone tumor.
  • He had recurrent bronchial carcinoid tumors that metastasized to liver and bones.
  • Combination therapy of octreotide and interferon alpha-2b significantly reduced the size of metastatic liver tumors and inhibited further growth of metastatic bone tumors for the last 27 months.
  • The use of octreotide may be a good option for controlling pain by metastatic bone disease and combination therapy of octreotide and interferon alpha-2b is worth to try for patients with inoperable metastatic carcinoid tumor.
  • [MeSH-major] Analgesics / therapeutic use. Bronchial Neoplasms / physiopathology. Carcinoid Tumor / secondary. Octreotide / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Back Pain / drug therapy. Bone Neoplasms / drug therapy. Bone Neoplasms / physiopathology. Bone Neoplasms / secondary. Humans. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Multiple Endocrine Neoplasia Type 1. Recombinant Proteins

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863961.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Analgesics; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b; RWM8CCW8GP / Octreotide
  •  go-up   go-down


2. Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, Buscombe J, Caplin ME: Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. Aliment Pharmacol Ther; 2009 Oct;30(7):733-40
Genetic Alliance. consumer health - Carcinoid Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
  • BACKGROUND: Octreotide LAR is an established treatment for malignant carcinoid syndrome.
  • AIM: To present long-terms results with octreotide LAR, assessing duration of clinical and objective response and treatment tolerance, in a large, homogeneous cohort of patients with malignant carcinoid syndrome.
  • METHODS: A total of 108 patients with metastatic midgut neuroendocrine tumours were included in this 8-year study.
  • In 17% of them, symptoms were controlled by just an increase of octreotide LAR dose, whilst the other patients required additional treatment.
  • Overall, in 45.3% of patients, symptoms were well controlled during the study period with only octreotide LAR, and no additional treatment was required.
  • CONCLUSIONS: Octreotide LAR treatment provides a sustained symptomatic response in about half of the patients with malignant carcinoid syndrome and contributes to disease stabilization for a longer period than previously described.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Gastrointestinal Agents / therapeutic use. Malignant Carcinoid Syndrome / drug therapy. Neuroendocrine Tumors / drug therapy. Octreotide / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19573169.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Gastrointestinal Agents; RWM8CCW8GP / Octreotide
  •  go-up   go-down


3. Zuetenhorst JM, Valdes Olmos RA, Muller M, Hoefnagel CA, Taal BG: Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours. Endocr Relat Cancer; 2004 Sep;11(3):553-61
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours.
  • Interferon (IFN) and meta-iodobenzylguanidin (MIBG) are active in metastatic carcinoids.
  • 131I-MIBG scintigraphy was performed prior to treatment, after 8 weeks of IFN and after unlabelled MIBG.
  • The tumour over non-tumour (T/NT) ratios were quantitatively determined by comparing counts in the centre of the tumour (liver metastases) with those in an adjacent area of normal liver uptake (T/NT1) and with abdominal background area (T/NT2).
  • The absolute uptake in tumour deposits was also increased if compared with the abdominal background (T/NT2: 23% increase after IFN and 83% increase after unlabelled MIBG).
  • The combination produced 91% of patients with stable disease (using World Health Organisation criteria) at computed tomography scan and a biochemical response (a reduction of at least 50% in urinary 5-hydroxyindolacetic acid excretion) in 39%.
  • IFN-alpha did not significantly improve tumour retention of 131I-MIBG.
  • In contrast, unlabelled MIBG significantly improved biodistribution and tumour uptake in 83%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoid Tumor / drug therapy. Carcinoid Tumor / secondary. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] 3-Iodobenzylguanidine / administration & dosage. Adult. Aged. Disease Progression. Female. Humans. Hydroxyindoleacetic Acid / urine. Interferon-alpha / administration & dosage. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Middle Aged. Recombinant Proteins. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Survival Rate. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15369454.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 35MRW7B4AD / 3-Iodobenzylguanidine; 54-16-0 / Hydroxyindoleacetic Acid; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


Advertisement
4. Shelat VG, Diddapur RK: Duodenal carcinoid: a rare cause of melaena in a cirrhotic patient. Singapore Med J; 2008 Aug;49(8):e198-201
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenal carcinoid: a rare cause of melaena in a cirrhotic patient.
  • Metastatic disease has a poor prognosis.
  • These are indolent tumours and hence role of chemotherapy is limited.
  • Radionuclide and biological therapies are emerging.
  • We report a 29-year-old man presenting with melaena and diagnosed as having a neuroendocrine tumour of the duodenum together with liver cirrhosis.
  • Standard Whipple's procedure was done and he is doing well at follow-up.
  • [MeSH-major] Carcinoid Tumor / complications. Duodenal Neoplasms / complications. Liver Cirrhosis / diagnosis. Liver Cirrhosis / therapy. Melena / diagnosis. Melena / etiology. Neuroendocrine Tumors / complications
  • [MeSH-minor] Adult. Duodenum / pathology. Endoscopy / methods. Humans. Male. Neoplasm Metastasis. Prognosis. Tomography, X-Ray Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18756332.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


5. Nakajima Y, Takagi H, Sohara N, Sato K, Kakizaki S, Nomoto K, Suzuki H, Suehiro T, Shimura T, Asao T, Kuwano H, Mori M, Nishikura K: Living-related liver transplantation for multiple liver metastases from rectal carcinoid tumor: a case report. World J Gastroenterol; 2006 Mar 21;12(11):1805-9
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living-related liver transplantation for multiple liver metastases from rectal carcinoid tumor: a case report.
  • Colonoscopy revealed submucosal tumor in the rectum, which was considered the primary lesion.
  • Endoscopic mucosal resection followed by histopathological examination revealed that the tumor was carcinoid.
  • The resected margin of the tumor was positive for malignant cells.
  • Two courses to transcatheter arterial chemotherapy for liver metastasis were ineffective.
  • Accordingly, the rectal tumor and metastatic lymph nodes were surgically resected.
  • Liver transplantation should be considered as a treatment option even in advanced case of carcinoid metastasis to the liver.
  • We also discuss the literature on liver transplantation for metastatic carcinoid tumor.
  • [MeSH-major] Carcinoid Tumor / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Liver Transplantation / methods. Rectal Neoplasms / pathology


6. Imtiaz KE, Monteith P, Khaleeli A: Complete histological regression of metastatic carcinoid tumour after treatment with octreotide. Clin Endocrinol (Oxf); 2000 Dec;53(6):755-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete histological regression of metastatic carcinoid tumour after treatment with octreotide.
  • Computerized tomography (CT) demonstrated multiple enhancing liver metastases with biopsy proven carcinoid metastases with no evidence of primary tumour at this stage.
  • Octreotide was initiated, resulting in marked improvement in carcinoid symptoms.
  • Repeat colonoscopy at this stage, showed an ileal tumour causing impending obstruction, necessitating urgent right hemicolectomy.
  • Histology demonstrated primary carcinoid tumour.
  • Autopsy revealed complete regression of hepatic carcinoid metastases.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoid Tumor / drug therapy. Ileal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Octreotide / therapeutic use

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Endocrinol (Oxf). 2000 Dec;53(6):663-4 [11155085.001]
  • (PMID = 11155099.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  •  go-up   go-down


7. Tetzlaff ED, Ajani JA: Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor. Int J Gastrointest Cancer; 2005;36(1):55-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor.
  • Carcinoid tumors are rare and often resistant to chemotherapy agents.
  • Although a slow-growing tumor, patients can have significant morbidity associated with carcinoid syndrome and patients will often die as a result of tumor progression.
  • We report the first case of a patient with a metastatic carcinoid tumor to respond to an oxaliplatin-based regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoid Tumor / drug therapy
  • [MeSH-minor] Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Metastasis. Organoplatinum Compounds / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1996 Dec;7(10):1065-70 [9037366.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):1124-7 [9849465.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Acta Oncol. 2003;42(7):672-92 [14690153.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):958-61 [8039124.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):893-900 [1735081.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4543-8 [12454110.001]
  • [Cites] Am J Pathol. 1928 May;4(3):181-212.19 [19969788.001]
  • [Cites] Cancer Treat Rev. 2005 Apr;31(2):90-105 [15847979.001]
  • [Cites] Ann Oncol. 1996 Jan;7(1):95-8 [9081400.001]
  • [Cites] Cancer Clin Trials. 1979 Winter;2(4):327-34 [93982.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):117-22 [15213627.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • (PMID = 16227636.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Corleto VD, Angeletti S, Schillaci O, Marignani M, Caratozzolo M, Panzuto F, Annibale B, Delle Fave G: Long-term octreotide treatment of metastatic carcinoid tumor. Ann Oncol; 2000 Apr;11(4):491-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term octreotide treatment of metastatic carcinoid tumor.
  • The optimal dosage of somatostatin analogs for the long-term control of carcinoid tumors has not yet been established.
  • Receptor alterations induced during long term treatment with somatostatin analogs have lead to consecutive drug dosage increases in order to control carcinoid disease.
  • In this report, we describe the rapid and effective control of tumor in a patient with metastatic carcinoid treated for nine years with a single daily dose of octreotide based on tumor marker levels.
  • We suggest that a single daily dose of octreotide strictly related to tumor marker secretion, could have played a role in the effective long-term therapy by avoiding the phenomenon of somatostatin receptor desensitisation.

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10847473.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Somatostatin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


9. Molenaar JP, Baten A, Blokx WA, Hoogendam A: Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate. Eur Urol; 2009 Nov;56(5):874-7; quiz 876
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate.
  • We present the case of an 81-yr-old man with a prostatic adenocarcinoma and a metastatic carcinoid.
  • Simultaneous occurrence of hormonally treated adenocarcinoma of the prostate and a carcinoid has been described before.
  • The pathogenesis of this coincidence is largely unclear; however, androgen deprivation therapy might play a key role in neuroendocrine differentiation of adenocarcinoma cells.
  • Early recognition of the carcinoid syndrome is crucial, as surgical cure is not possible after metastasis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Anilides / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Carcinoid Tumor / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary. Nitriles / therapeutic use. Prostatic Neoplasms / drug therapy. Tosyl Compounds / therapeutic use
  • [MeSH-minor] Aged, 80 and over. Biopsy. Humans. Male. Malignant Carcinoid Syndrome / drug therapy. Positron-Emission Tomography. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19171417.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Tosyl Compounds; 51110-01-1 / Somatostatin; A0Z3NAU9DP / bicalutamide
  •  go-up   go-down


10. Bouvier N, Zengerling V, Halley A, Le Pennec V, Le Rochais JP, Madelaine J, Galateau-Salle F, Bergot E, Zalcman G: [Primitive metastasizing bronchial carcinoid with long survival]. Rev Mal Respir; 2007 Jan;24(1):63-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primitive metastasizing bronchial carcinoid with long survival].
  • [Transliterated title] Carcinoïde bronchique d'emblée multimétastatique et survie prolongée. Une entité anatomo-clinique peu connue: place de l'imagerie fonctionnelle.
  • BACKGROUND: Metastatic bronchial carcinoid tumours are rare but some patients have a prolonged survival.
  • OBSERVATION: A 57 year old patient was referred for dyspnoea on exertion revealing an upper left lobar tumour, with carcinoid syndrome.
  • The assessment enabled to find out a bronchial carcinoid tumour with liver and bone metastases, highlighted by positron-emission tomography and pentetreotide SPECT.
  • A chemotherapy proved to be ineffective and upper left lobectomy was carried out because of the risk of pulmonary atelectasis.
  • The patient was alive 44 months after diagnosis (56 months after first computed tomography).
  • CONCLUSION: Metastatic bronchial carcinoid tumours are rare.
  • They keep a metastatic potential, the histological type remaining the major prognosis factor.
  • Carcinoid syndrome is suggestive.
  • The assessment of extra-thoracic disease extent benefits by contribution of new functional imagery techniques such as the pentetreotide SPECT and positron-emission tomography.
  • The management is essentially symptomatic since there is no effective chemotherapy.
  • [MeSH-minor] Humans. Male. Middle Aged. Survivors. Time Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268367.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


11. Bapat U, Mackinnon NA, Spencer MG: Carcinoid tumours of the larynx. Eur Arch Otorhinolaryngol; 2005 Mar;262(3):194-7
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoid tumours of the larynx.
  • The tumour histology and prognosis correlate closely.
  • The typical carcinoid tumours are well differentiated with a benign course.
  • Conservative surgery for local disease is the treatment and is associated with good survival.
  • The atypical carcinoid tumours are poorly differentiated with an aggressive course.
  • Response to radiotherapy and chemotherapy is poor.
  • The treatment of choice is adequate total excision of the lesion with neck dissection if there is clinical evidence of cervical lymphadenopathy and a careful follow-up so as to recognise and treat any metastatic spread.
  • [MeSH-major] Carcinoid Tumor / pathology. Laryngeal Neoplasms / pathology
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laryngol Otol. 1986 Dec;100(12):1421-6 [3805883.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1992 Aug;101(8):710-4 [1323230.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Mar;21(1):5-13 [12071530.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1987 May-Jun;96(3 Pt 1):315-21 [3300506.001]
  • [Cites] J Laryngol Otol. 1998 Sep;112(9):827-34 [9876371.001]
  • [Cites] Laryngoscope. 1985 Jun;95(6):715-9 [3889527.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 1991;53(4):210-9 [1653928.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 Apr;120(4):536-9 [10187951.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1991 Dec;117(12):1395-9 [1845268.001]
  • [Cites] Laryngoscope. 1995 Aug;105(8 Pt 1):789-94 [7630288.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1989 Oct;98(10):780-90 [2552894.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 1991;53(4):194-209 [1891252.001]
  • [Cites] Laryngorhinootologie. 2000 Oct;79(10):573-8 [11089204.001]
  • [Cites] Cancer. 1982 Jan 15;49(2):343-9 [6119151.001]
  • [Cites] J Laryngol Otol. 1991 Dec;105(12):1031-5 [1664846.001]
  • [Cites] J Laryngol Otol. 1997 Jan;111(1):89-91 [9292144.001]
  • (PMID = 15164214.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Dworakowska D, Gueorguiev M, Laji K, Grossman AB: Multimodality palliative treatment of (111)In-pentetreotide negative/(123)I-MIBG positive metastatic carcinoid - a case report. Endokrynol Pol; 2008 Jul-Aug;59(4):342-7
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality palliative treatment of (111)In-pentetreotide negative/(123)I-MIBG positive metastatic carcinoid - a case report.
  • Patients with carcinoid tumours frequently present with metastatic disease.
  • There are only a few therapeutic options for these patients, and the main goal of palliative treatment is to reduce symptoms and thus to improve quality of life.
  • Current therapy includes surgical resection, hepatic artery embolisation, chemotherapy and somatostatin analogue treatment; however, all these options have limitations.
  • It seems probable that therapeutic modalities based on radiopharmaceuticals may provide better therapy, not only in relation to symptom reduction but may also improve patient survival.
  • In this case report we present a 46-year-old woman with a symptomatic carcinoid, who at the time of diagnosis had liver and abdominal lymph node metastases, the primary tumour being located in the terminal ileum. (111)In-pentetreotide scanning was negative, whereas (123)I-MIBG scanning showed high avidity in the tumour tissue.
  • After right hemicolectomy, two courses of (131)I-MIBG treatment were given (12.95 GBq and 12 GBq, respectively).
  • Octreotide therapy was given empirically only for a short time and was stopped because of drug intolerance.
  • The patient underwent tricuspid and pulmonary valve replacement because of her carcinoid heart disease, followed by two courses of embolisation of liver metastases.
  • While (131)I-MIBG therapy reduced the patient's symptoms of flushing and diarrhoea, there has not yet been any effect on tumour response or 5-HIAA production.
  • [MeSH-major] 3-Iodobenzylguanidine / therapeutic use. Carcinoid Tumor / secondary. Carcinoid Tumor / therapy. Ileal Neoplasms / therapy. Palliative Care
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colectomy. Female. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Octreotide / analogs & derivatives. Octreotide / analysis. Pentetic Acid / analogs & derivatives. Pentetic Acid / analysis

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18777505.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 142694-57-3 / SDZ 215-811; 35MRW7B4AD / 3-Iodobenzylguanidine; 7A314HQM0I / Pentetic Acid; RWM8CCW8GP / Octreotide
  •  go-up   go-down


13. Hubalewska-Dydejczyk A, Szybiński P, Fröss-Baron K, Mikolajczak R, Huszno B, Sowa-Staszczak A: (99m)Tc-EDDA/HYNIC-octreotate - a new radiotracer for detection and staging of NET: a case of metastatic duodenal carcinoid. Nucl Med Rev Cent East Eur; 2005;8(2):155-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (99m)Tc-EDDA/HYNIC-octreotate - a new radiotracer for detection and staging of NET: a case of metastatic duodenal carcinoid.
  • We present a case of a 47-year-old man with disseminated duodenal carcinoid.
  • The patient had been operated due to the tumour mass detected in pancreatic head area.
  • Histopathology revealed carcinoid of the duodenal wall with local lymph node and liver metastases.
  • The patient was qualified for chemotherapy stopped due to severe leucopenia. (99m)Tc EDDA/HYNIC-octreotate scintigraphy was performed for staging and to determine SSTR status of the tumour before planned 90Y-DOTATATE therapy.
  • The multiple metastatic lesions were detected all over the body.
  • On the basis of SRS result the patient was qualified for 90Y-DOTA-TATE therapy.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437406.001).
  • [ISSN] 1506-9680
  • [Journal-full-title] Nuclear medicine review. Central & Eastern Europe
  • [ISO-abbreviation] Nucl Med Rev Cent East Eur
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium 99m EDDA-HYNIC-Tyr(3)-octreotide
  •  go-up   go-down


14. Bodelier AG, Haak HR: [Gastroenteropancreatic neuroendocrine tumours (carcinoid tumours): definition, clinical aspects, diagnosis and therapy]. Ned Tijdschr Geneeskd; 2006 Aug 26;150(34):1868-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastroenteropancreatic neuroendocrine tumours (carcinoid tumours): definition, clinical aspects, diagnosis and therapy].
  • [Transliterated title] Gastro-enteropancreatische neuro-endocriene tumoren (carcinoïde tumoren): definitie, kliniek, diagnostiek en therapie.
  • Carcinoid tumours are rare neuroendocrine tumours.
  • In 2000 the WHO developed a new classification which gives a better description of the characteristics and biological behaviour of the tumour.
  • Their advised designation is gastroenteropancreatic neuroendocrine tumour (GEP-NET).
  • In the recent past years new positron emission tomography (PET) tracers have been developed and PET scanning is likely to become an important tool in the near future.
  • Surgical resection is the treatment of first choice for a patient with a GEP-NET.
  • In metastatic disease a number of forms ofpalliative treatment are possible.
  • Cytotoxic chemotherapy seems only to be effective in aggressive, poorly-differentiated tumours.
  • Therapy with somatostatin analogues leads to objective tumour regression in a minority of patients only.
  • New advances in peptide receptor radionuclide therapy using radioactive-labelled somatostatin analoga are showing better results.
  • [MeSH-major] Carcinoid Tumor / diagnosis. Gastrointestinal Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Humans. Positron-Emission Tomography / methods. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ned Tijdschr Geneeskd. 2006 Oct 28;150(43):2401; author reply 2401 [17100134.001]
  • [CommentIn] Ned Tijdschr Geneeskd. 2006 Oct 28;150(43):2401-3; author reply 2403 [17103497.001]
  • (PMID = 16970007.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 51110-01-1 / Somatostatin
  • [Number-of-references] 35
  •  go-up   go-down


15. Kölby L, Persson G, Franzén S, Ahrén B: Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg; 2003 Jun;90(6):687-93
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.
  • BACKGROUND: Midgut carcinoid tumours often present with widespread disease making curative surgery impossible.
  • Medical treatment therefore plays a major role in the treatment of these patients.
  • METHODS: In this prospective randomized study, the effect of interferon (IFN) alpha on survival and risk of tumour progression was evaluated in 68 patients with midgut carcinoid tumours metastatic to the liver.
  • All patients had undergone primary surgical treatment and hepatic arterial embolization of liver metastases before randomization.
  • Patients were randomized to treatment with either octreotide alone (n = 35) or octreotide in combination with IFN-alpha (n = 33).
  • However, patients treated with IFN-alpha had a significantly reduced risk of tumour progression during follow-up (P = 0.008).
  • CONCLUSION: Addition of IFN-alpha to octreotide may retard tumour growth in patients with midgut carcinoid tumours.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoid Tumor / drug therapy. Gastrointestinal Neoplasms. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy. Octreotide / therapeutic use
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Disease Progression. Female. Humans. Hydroxyindoleacetic Acid / urine. Lipids / blood. Male. Middle Aged. Prospective Studies. Risk Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • [CommentIn] Cancer Treat Rev. 2003 Dec;29(6):565-9 [14585268.001]
  • (PMID = 12808615.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Lipids; 54-16-0 / Hydroxyindoleacetic Acid; RWM8CCW8GP / Octreotide
  •  go-up   go-down


16. Toumpanakis C, Standish RA, Baishnab E, Winslet MC, Caplin ME: Goblet cell carcinoid tumors (adenocarcinoid) of the appendix. Dis Colon Rectum; 2007 Mar;50(3):315-22
SciCrunch. The Antibody Registry: Reagent: Antibodies .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Goblet cell carcinoid tumors (adenocarcinoid) of the appendix.
  • Right hemicolectomy was performed in all except one, who subsequently developed metastases.
  • Ki67 index was greater than 20 percent in all of them, while in only one with local tumor.
  • Combination chemotherapy with either cisplatin plus etoposide or with 5-fluorouracil, cisplatin, and streptozotocin was administered to all patients with metastases resulting in temporary stabilization of disease.
  • Ki67 index appears to predict tumor behavior.
  • Chemotherapy may have efficacy in metastatic disease, however, more data are required to determine this and the optimal regimen.
  • [MeSH-major] Appendiceal Neoplasms / diagnosis. Carcinoid Tumor / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendectomy. Biomarkers, Tumor / analysis. Cisplatin / administration & dosage. Colectomy. Combined Modality Therapy. Diagnosis, Differential. Etoposide / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Streptozocin / administration & dosage

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17195086.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 5W494URQ81 / Streptozocin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Kaltsas GA, Mukherjee JJ, Isidori A, Kola B, Plowman PN, Monson JP, Grossman AB, Besser GM: Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil. Clin Endocrinol (Oxf); 2002 Aug;57(2):169-83
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
  • OBJECTIVE: Combination chemotherapy with the two agents streptozotocin (SZT), which is a nitrosurea, and 5-fluorouracil (5-FU), an alkylating agent, has a long-established role in the treatment of neuroendocrine tumours; however, it is often accompanied by considerable toxicity, and it has not been assessed in a comparative manner with other current chemotherapy regimens.
  • In order to assess the therapeutic response and adverse effects using an alternative nitrosurea, lomustine (CCNU), which has a different side-effect profile, in combination with 5-FU, we have reviewed all patients with neuroendocrine tumours who received this form of treatment in our department.
  • DESIGN: Retrospective analysis of the case notes of patients with metastatic neuroendocrine tumours who received treatment with the combination of CCNU and 5-FU, and who were followed up according to a defined protocol in a given time frame.
  • PATIENTS: Thirty-one patients with metastatic neuroendocrine tumours (18 with carcinoid tumours, five islet-cell tumours, five chromaffin-cell tumours and three medullary carcinoma of the thyroid) treated with the combination of CCNU and 5-FU, and when necessary additional therapy, over a 22-year period, were included in this analysis.
  • MEASUREMENTS: The symptomatic, hormonal and tumoural responses before and after chemotherapy with the combination of CCNU and 5-FU over a median follow-up duration of 25 months (range 9-348 months) were recorded.
  • Of the 31 patients (16 males; median age 52 years, range 20-86 years), eight (four males; median age 61 years, range 30-74 years) were treated with the combination of CCNU and 5-FU alone (Group 1), whereas the other 23 patients (12 males; median age 47 years, range 20-86 years) received additional therapy with other chemotherapeutic regimens, somatostatin analogues, alpha-interferon or radiolabelled meta-iodobenzylguanidine (131I-MIBG) therapy (Group 2).
  • RESULTS: A total of 121 therapeutic cycles was administered (mean 3.9, range 1-14 cycles).
  • None of the patients obtained a complete tumour response.
  • A partial tumour response (not a complete but a 50% or greater reduction of all measurable tumour) was seen in six out of the 29 patients (21%) (four out of eight in Group 1 and two out of 21 in Group 2, respectively).
  • There was no tumour progression in eight out of the 29 patients (27.5%) (one out of eight in Group 1 and seven out of 21 in Group 2, respectively).
  • The overall 5-year survival rate was 42% (95% CI, 17-67%) for all patients and 50% (95% CI, 18-83%) for the carcinoid group alone, according to Kaplan-Meier analysis.
  • Nine out of the 15 (60%) patients with carcinoid tumours who presented with symptoms obtained a symptomatic response, five out of 10 patients (50%) a hormonal response, and four out of 16 (25%) patients a partial tumoural response, respectively.
  • No chemotherapy-related death was recorded.
  • CONCLUSIONS: Chemotherapy with CCNU and 5-FU, either alone or in combination with other therapeutic modalities, produces considerable symptomatic and hormonal improvement and moderate tumour regression/stabilization according to currently accepted WHO criteria, particularly in patients with metastatic gastroenteropancreatic neuroendocrine tumours with minimal adverse effects.
  • It may therefore be a valuable additional therapeutic option, particularly for well-differentiated carcinoid and islet-cell tumours, but mainly reserved for when there is no response or progression of the disease after currently available first-line treatment with somatostatin analogues or radiopharmaceuticals.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neuroendocrine Tumors / drug therapy. Neuroendocrine Tumors / secondary
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Lomustine / administration & dosage. Male. Middle Aged. Retrospective Studies. Survival Rate

  • Hazardous Substances Data Bank. LOMUSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12153595.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 7BRF0Z81KG / Lomustine; U3P01618RT / Fluorouracil
  • [Number-of-references] 50
  •  go-up   go-down


18. Dominguez S, Denys A, Madeira I, Hammel P, Vilgrain V, Menu Y, Bernades P, Ruszniewski P: Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol; 2000 Feb;12(2):151-7
Hazardous Substances Data Bank. STREPTOZOTOCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours.
  • BACKGROUND: Hepatic arterial chemoembolization (CE) with anthracyclines is an effective treatment for progressive liver metastases of digestive endocrine tumours.
  • Streptozotocin (STZ) is widely used for systemic chemotherapy, but its efficacy by the hepatic arterial route has not been evaluated.
  • All patients had progressive liver metastases from either a carcinoid tumour (eight patients) or an islet cell carcinoma (ICC) (seven patients) that had increased in size (> or = 25%) before CE.
  • Five patients had the carcinoid syndrome.
  • RESULTS: An objective response was achieved in 8/15 patients (53%; median duration of 10.5 months) whatever the primary tumour (carcinoid or ICC).
  • The carcinoid syndrome disappeared in 3/5 patients for 10, 11 and 17 months, respectively.
  • CONCLUSION: Hepatic arterial chemoembolization with STZ is an effective treatment for patients with liver metastases caused by digestive endocrine tumours.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoid Tumor / therapy. Carcinoma, Islet Cell / therapy. Chemoembolization, Therapeutic. Intestinal Neoplasms / pathology. Liver Neoplasms / therapy. Streptozocin / administration & dosage
  • [MeSH-minor] Adult. Aged. Female. Hepatic Artery. Humans. Male. Middle Aged. Prospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Gastroenterol Hepatol. 2000 Feb;12(2):141-3 [10741925.001]
  • (PMID = 10741928.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 5W494URQ81 / Streptozocin
  •  go-up   go-down


19. Basaria S, McCarthy EF, Belzberg AJ, Ball DW: Case of an ivory vertebra. J Endocrinol Invest; 2000 Sep;23(8):533-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differential diagnosis of an osteoblastic vertebral lesion (ivory vertebra) includes metastatic prostate cancer, lung cancer, lymphoma, osteosarcoma and Paget's disease.
  • He failed to respond to conventional bisphosphate therapy.
  • The review of the original biopsy specimen showed metastatic carcinoid tumor involving the bone marrow.
  • The various features of carcinoid tumors metastasizing to the skeleton are briefly reviewed.
  • [MeSH-major] Carcinoid Tumor / diagnosis. Liver Neoplasms / diagnosis. Spinal Neoplasms / diagnosis
  • [MeSH-minor] Alendronate / therapeutic use. Alkaline Phosphatase / blood. Biopsy. Bone Marrow / pathology. Diagnosis, Differential. Diphosphonates / therapeutic use. Humans. Lumbar Vertebrae. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Osteitis Deformans / drug therapy. Osteoblasts / pathology. Technetium. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Alendronic acid .
  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1973 May;107(2):327-30 [4695897.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2B):1243-9 [9615795.001]
  • [Cites] Thorax. 1977 Aug;32(4):509-11 [929495.001]
  • [Cites] Clin Exp Rheumatol. 1994 Mar-Apr;12(2):228-9 [8039297.001]
  • [Cites] Skeletal Radiol. 1991;20(2):149-51 [2020865.001]
  • [Cites] Clin Biochem. 1987 Aug;20(4):225-30 [3319285.001]
  • (PMID = 11021770.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Diphosphonates; 7440-26-8 / Technetium; EC 3.1.3.1 / Alkaline Phosphatase; OYY3447OMC / pamidronate; X1J18R4W8P / Alendronate
  •  go-up   go-down


20. Sywak MS, Pasieka JL, McEwan A, Kline G, Rorstad O: 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors. World J Surg; 2004 Nov;28(11):1157-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors.
  • The management of metastatic neuroendocrine tumors incorporates multimodal therapy with surgery, biotherapy, and chemotherapy.
  • Tumor-targeted therapies using radiolabeled octreotide and metaiodobenzylguanidine (mIBG) represent a novel treatment approach.
  • The aim of this study was to evaluate the effectiveness of 131I-mIBG in the treatment of metastatic midgut carcinoid tumors. survival outcomes were assessed for patients treated at two regional cancer centers and then compared.
  • One center used 131I-mIBG routinely in the management of metastatic carcinoid tumors (center A), and the other did not use this modality (center B).
  • Only patients with histologically proven metastatic carcinoid tumor shown, or thought most likely, to be of midgut origin were included in the study.
  • During the period 1980 to 2002, a series of 58 patients from center A with metastatic carcinoid tumor arising from the midgut underwent multimodality therapy with the addition of 131I-mIBG.
  • The median dose of 131I-mIBG administered was 6751 MBq, and there was an average of 2.8 treatments per patient.
  • During the same period, 58 patients with metastatic carcinoid were treated at center B with similar multimodality therapy without the use of 131I-mIBG therapy.
  • Although retrospective in nature, this study suggests that the addition of 131I-mIBG therapy to the treatment protocol of patients with metastatic midgut carcinoid tumors prolongs survival.
  • [MeSH-major] 3-Iodobenzylguanidine / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoid Tumor / drug therapy. Intestinal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Ileal Neoplasms / drug therapy. Ileal Neoplasms / pathology. Jejunal Neoplasms / drug therapy. Jejunal Neoplasms / pathology. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Peritoneal Neoplasms / secondary. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] South Med J. 1989 Dec;82(12):1501-5 [2595419.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):813-29 [9024720.001]
  • [Cites] J Endocrinol Invest. 1997 Dec;20(11):648-58 [9492103.001]
  • [Cites] Eur J Surg Oncol. 2002 Apr;28(3):243 [11944956.001]
  • [Cites] Eur J Nucl Med. 1994 Jun;21(6):561-81 [7915987.001]
  • [Cites] Br J Surg. 2003 Jun;90(6):687-93 [12808615.001]
  • [Cites] Nucl Med Commun. 1993 Oct;14(10):856-61 [8233228.001]
  • [Cites] Eur J Surg Oncol. 2001 Jun;27(4):404-8 [11417988.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2204-10 [11596039.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1976 Jul;84(4):322-30 [961424.001]
  • [Cites] World J Surg. 2002 Feb;26(2):257-63 [11865357.001]
  • [Cites] J Nucl Biol Med. 1991 Oct-Dec;35(4):346-8 [1726678.001]
  • [Cites] Clin Nucl Med. 1986 Mar;11(3):150-2 [3956021.001]
  • [Cites] Transplant Proc. 1998 Nov;30(7):3298-300 [9838458.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Eur J Cancer. 1992;28A(10):1647-50 [1382492.001]
  • [Cites] Am Surg. 1985 Jan;51(1):37-41 [3966721.001]
  • [Cites] J Clin Oncol. 1996 Jun;14 (6):1829-38 [8656251.001]
  • [Cites] J Surg Oncol. 2002 Mar;79(3):180-7 [11870669.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Jul;55(1):47-60 [11453952.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):770-6 [10679645.001]
  • [Cites] ANZ J Surg. 2002 Sep;72 (9):635-8 [12269913.001]
  • [Cites] Acta Oncol. 1991;30(4):523-7 [1854510.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):815-21; discussion 822-3 [10363895.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1999 Oct;11(10 ):1157-64 [10524647.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9343-8 [9256484.001]
  • [Cites] J Heart Valve Dis. 1997 Nov;6(6):625-30 [9427132.001]
  • [Cites] Ital J Gastroenterol Hepatol. 1997 Apr;29(2):135-7 [9646193.001]
  • [Cites] Circulation. 1995 Aug 15;92 (4):790-5 [7641358.001]
  • (PMID = 15490060.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 35MRW7B4AD / 3-Iodobenzylguanidine
  •  go-up   go-down


21. Kasi VS, Ahsanuddin AN, Gilbert C, Orr L, Moran J, Sorrell VL: Isolated metastatic myocardial carcinoid tumor in a 48-year-old man. Mayo Clin Proc; 2002 Jun;77(6):591-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated metastatic myocardial carcinoid tumor in a 48-year-old man.
  • The mass, which involved the subvalvar right ventricular free wall, was resected and determined to be a metastatic carcinoid tumor by histologic and immunohistochemical analysis.
  • Further investigation revealed the presence of a midgut carcinoid tumor located within the terminal ileum, which was also resected surgically.
  • The patient recovered well after surgery and adjunctive chemotherapy.
  • To our knowledge, this is the first report of comprehensive nuclear and echocardiographic imaging, supplemented by surgical and pathologic findings, in an asymptomatic patient with isolated myocardial metastasis of an ileal carcinoid tumor.
  • [MeSH-major] Carcinoid Tumor / secondary. Heart Neoplasms / complications. Heart Neoplasms / secondary. Ileal Neoplasms / pathology. Ventricular Dysfunction, Right / etiology

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Mayo Clin Proc 2002 Dec;77(12):1396. Ahsanudin Arshad N [corrected to Ahsanuddin Arshad N]
  • (PMID = 12059131.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Aparicio T, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry E, Schlumberger M, Rougier P: Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer; 2001 May;37(8):1014-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.
  • 35 consecutive patients with documented tumour progression were treated with somatostatin analogues.
  • Treatment consisted of subcutaneous (s.c.) octreotide, 100 microg thrice daily for 17 patients, intramuscular lanreotide, 30 mg/every 14 days for 11 patients and for 7 patients both somatostatin analogues were used successively during the follow-up.
  • Primary tumour sites were the small intestine (n=12), pancreas (n=13), lungs (n=5), and other sites (n=5).
  • 18 patients had the carcinoid syndrome with flushing and/or diarrhoea.
  • The median duration of treatment was 7 months.
  • Treatment was discontinued in 3 patients due to side-effects.
  • Somatostatin analogue treatment resulted in one partial response (3%) and 20 cases of stabilisation (57%) in 35 patients with progressive NET.
  • A slow tumour growth rate before treatment is predictive of a good response to somatostatin analogues which could be considered an option for first-line treatment.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Neuroendocrine Tumors / drug therapy. Octreotide / therapeutic use. Peptides, Cyclic / therapeutic use. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11334727.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


23. Stuart K, Levy DE, Anderson T, Axiotis CA, Dutcher JP, Eisenberg A, Erban JK, Benson III AB, Eastern Cooperative Oncology Group: Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs; 2004 Jan;22(1):75-81
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group.
  • PURPOSE: To determine the safety and efficacy of treatment with gamma interferon (IFNgamma) in patients with metastatic carcinoid tumor.
  • Treatment consisted of IFNgamma subcutaneously at a daily dose of 0.1 mg/m(2).
  • RESULTS: Patients received treatment with IFNgamma for a median of 17.9 weeks (range 2-175).
  • Toxicity was generally mild and expected: 61% experienced noninfected fever and 21% developed granulocytopenia.
  • Median time to progression was 5.5 months (95% confidence interval 3.9-11.1).
  • DISCUSSION: This Phase II study demonstrated that therapy with IFNgamma in patients with metastatic carcinoid tumor was well-tolerated, but did not produce significant antitumor effects.
  • The overall results were somewhat comparable to those previously seen with alpha interferons as well as cytotoxic drugs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-gamma / therapeutic use. Malignant Carcinoid Syndrome / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1996 Jan 15;77(2):402-8 [8625251.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Feb;85(4):1242-6 [3124115.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):813-29 [9024720.001]
  • [Cites] Anticancer Drugs. 1996 Feb;7(2):175-81 [8740722.001]
  • [Cites] Cancer Treat Rep. 1986 Dec;70(12):1459-60 [3791259.001]
  • [Cites] Acta Oncol. 1993;32(2):235-8 [7686766.001]
  • [Cites] Acta Endocrinol (Copenh). 1992 Feb;126(2):184-5 [1371898.001]
  • [Cites] Am J Med. 1987 May 29;82(5B):4-16 [2884878.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1295-300 [11697843.001]
  • [Cites] Oncologist. 1998;3(5):339-345 [10388123.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):547-9 [1702352.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):346-50 [3121172.001]
  • [Cites] J Biol Chem. 1988 Feb 5;263(4):2041-8 [3123485.001]
  • [Cites] J Chemother. 1991 Oct;3(5):328-31 [1839743.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1255-9 [6238136.001]
  • [Cites] Digestion. 1994;55 Suppl 3:3-10 [7698535.001]
  • [Cites] J Immunol. 1987 Oct 1;139(7):2414-8 [2443564.001]
  • [Cites] South Med J. 1972 Nov;65(11):1325-7 [4263638.001]
  • [Cites] Br J Haematol. 1991 Oct;79 Suppl 1:74-7 [1834159.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1486-92 [7751896.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1502-22 [2443618.001]
  • [Cites] J Clin Oncol. 1983 Nov;1(11):727-40 [6199469.001]
  • [Cites] Proc R Soc Med. 1972 Feb;65(2):164-5 [4263805.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):858-68 [10080850.001]
  • [Cites] Eur J Cancer. 1992;28A(10):1650-3 [1382493.001]
  • [Cites] Surgery. 1994 Dec;116(6):1111-6; discussion 1116-7 [7985095.001]
  • [Cites] Acta Oncol. 1993;32(2):225-9 [7686765.001]
  • [Cites] Acta Oncol. 1993;32(2):231-3 [8323762.001]
  • [Cites] Cancer Treat Rep. 1979 May;63(5):795-6 [222449.001]
  • [Cites] Cancer. 1987 Dec 15;60(12):2891-5 [2960446.001]
  • [Cites] Cancer Treat Rep. 1983 Jun;67(6):583-5 [6861165.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1505-8 [8111718.001]
  • [Cites] Cancer Clin Trials. 1979 Winter;2(4):327-34 [93982.001]
  • [Cites] Cancer Treat Rep. 1986 Nov;70(11):1297-304 [2429764.001]
  • (PMID = 14707497.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA07190; United States / NCI NIH HHS / CA / CA13650; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA80775
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


24. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG, Eastern Cooperative Oncology Group: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol; 2005 Aug 1;23(22):4897-904
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.
  • PURPOSE: Optimal treatments for metastatic carcinoid tumor remain undefined, and the role of chemotherapy for symptomatic patients with progressive disease is uncertain.
  • PATIENTS AND METHODS: Two hundred forty-nine patients with advanced carcinoid tumors were randomized to either doxorubicin with fluorouracil (FU/DOX) or streptozocin with fluorouracil (FU/STZ).
  • Patients crossed over to the dacarbazine (DTIC) treatment after disease progression following first-line treatment (either FU/DOX or FU/STZ), and 73 patients were assigned to one of these three treatments based on their previous treatment or on abnormal baseline cardiac or renal function.
  • The response rate of crossover DTIC treatment was 8.2%, with a median survival of 11.9 months.
  • Hematologic toxicities were the major treatment-related toxicities for both FU/DOX and FU/STZ, and mild to moderate renal toxicity was reported in 40 (34.8%) of 115 patients in the FU/STZ arm.
  • CONCLUSION: Response to all three treatment regimens were modest.
  • FU/STZ improved survival compared with the doxorubicin-based regimen, suggesting that the combination should be considered to be an active regimen of therapy when chemotherapy is judged to be an option for selected patients with carcinoid tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoid Tumor / drug therapy

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16051944.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA13650; United States / NCI NIH HHS / CA / CA15488; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA233818; United States / NCI NIH HHS / CA / CA66636
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 5W494URQ81 / Streptozocin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Tanvetyanon T, Choudhury AM: Hypocalcemia and azotemia associated with zoledronic acid and interferon alfa. Ann Pharmacother; 2004 Mar;38(3):418-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe severe hypocalcemia and acute renal failure associated with zoledronic acid and interferon alfa in a patient with metastatic carcinoid tumors.
  • CASE SUMMARY: A 39-year-old white man with metastatic carcinoid tumor tolerated treatment with subcutaneous long-acting octreotide monthly and interferon alfa 6 million units 3 times weekly for 6 months.
  • Although the first infusion went well, the patient developed severe hypocalcemia and acute renal failure after the second zoledronic infusion.
  • DISCUSSION: Bisphosphonates may infrequently cause symptomatic hypocalcemia, especially among patients who have vitamin D deficiency or hypoparathyroidism or receive treatment with an aminoglycoside.
  • Since therapeutic indications of both interferon alfa and zoledronic acid continue to expand, clinicians should be aware of these serious adverse reactions and potential interaction.
  • Supportive treatment with hydration, calcium supplement, and oral calcitriol resulted in resolution of hypocalcemia, but only partial improvement of azotemia.
  • CONCLUSIONS: In our patient with metastatic carcinoid tumor, treatment with zoledronic acid and interferon alfa was associated with symptomatic hypocalcemia and acute renal failure.
  • [MeSH-minor] Adult. Carcinoid Tumor / drug therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14970365.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphosphonates; 0 / Imidazoles; 0 / Interferon-alpha; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


26. Wang HY, Chen MJ, Yang TL, Chang MC, Chan YJ: Carcinoid tumor of the duodenum and accessory papilla associated with polycythemia vera. World J Gastroenterol; 2005 Jun 28;11(24):3794-6
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoid tumor of the duodenum and accessory papilla associated with polycythemia vera.
  • Carcinoid tumors have been reported in a wide range of organs but most frequently involve the gastrointestinal tract; however, duodenal carcinoid tumors are rare.
  • The biopsy taken showed a carcinoid tumor.
  • He received periodic phlebotomy and hydroxyurea treatment.
  • The possible origin of UGI bleeding by a duodenal carcinoid tumor, although rare, should be considered.
  • There has been one case report of a duodenal carcinoid tumor that involved accessory papilla of the pancreas divisum and one case report of metastatic carcinoid tumor associated with polycythemia vera.
  • It is different in our patient as compared with the latter report, which mentioned a polycythemia vera patient who was found to have a metastatic carcinoid in the 17 years follow-up period.
  • Chemotherapy had been given before the carcinoid tumor was revealed.
  • Our patient had no previous chemotherapy for polycythemia vera before he was found to have duodenal carcinoid tumor; this excludes the possibility of chemotherapy induced carcinoid tumor, although it had been suspected in the previous report.
  • [MeSH-major] Carcinoid Tumor / complications. Duodenal Neoplasms / complications. Pancreatic Ducts / pathology. Polycythemia Vera / complications

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • Genetic Alliance. consumer health - Polycythemia vera.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968742.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4316038
  •  go-up   go-down


27. Ducreux M, Baudin E, Schlumberger M: [Treatment strategy of neuroendocrine tumors]. Rev Prat; 2002 Feb 1;52(3):290-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment strategy of neuroendocrine tumors].
  • [Transliterated title] Stratégie de traitement des tumeurs neuro-endocrines.
  • Therapeutic strategy of neuroendocrine tumours is complex, due to their heterogeneity and to the fact that although generally slow growing, a significant proportion demonstrates aggressive tumour growth.
  • Symptomatic carcinoid syndrome and various pancreatic endocrine tumours with symptomatic syndromes are well controlled with somatostatin analogues.
  • Surgery remains the mainstay of treatment if the tumour can be resected.
  • Metastatic pancreatic neuroendocrine tumour are treated when resection is not feasible with combination chemotherapy using adriamycin and streptozotocin, which remains a standard of care.
  • In well differentiated tumour of the gut or the lung there is no clear standard of chemotherapy and treatment vary according to the tumour course.
  • In indolent cases, somatostatin analogues are the best treatment, in case of aggressive tumours chemoembolisation should be preferred when the disease is located or predominant in the liver.
  • Poorly differentiated tumours are treated by combination chemotherapy with etoposide and cisplatin, and surgery has no indication.
  • Gastrinoma and other pancreatic tumours arising in the context of multiple endocrine neoplasia type I disease need a specific therapeutic strategy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Growth Hormone / therapeutic use. Hormones / therapeutic use. Neuroendocrine Tumors / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Antibiotics, Antineoplastic / therapeutic use. Chemoembolization, Therapeutic. Doxorubicin / therapeutic use. Gastrinoma / drug therapy. Humans. Malignant Carcinoid Syndrome / drug therapy. Multiple Endocrine Neoplasia. Neoplasm Metastasis. Streptozocin / therapeutic use

  • MedlinePlus Health Information. consumer health - Hormones.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11925720.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Hormones; 5W494URQ81 / Streptozocin; 80168379AG / Doxorubicin; 9002-72-6 / Growth Hormone
  • [Number-of-references] 23
  •  go-up   go-down


28. Gerencer RZ, Patel U, Hunter C, Heffernan JT: The role of endoscopic sinus surgery in the diagnosis and treatment of metastatic orbital carcinoid tumors. Ear Nose Throat J; 2007 Mar;86(3):157-61
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of endoscopic sinus surgery in the diagnosis and treatment of metastatic orbital carcinoid tumors.
  • Carcinoid tumor metastatic to the orbit is a rare occurrence.
  • We report such a case in a patient with a carcinoid metastasis that was found in the medial rectus muscle.
  • We also discuss the treatment of metastatic orbital carcinoid in the hope that we will increase awareness of the utility of transnasal endoscopy in facilitating both the diagnosis and treatment of posteromedial orbital pathology.
  • [MeSH-major] Carcinoid Tumor / secondary. Carcinoid Tumor / surgery. Endoscopy / methods. Orbital Neoplasms / secondary. Orbital Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Middle Aged

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427777.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Arvidsson Y, Bergström A, Arvidsson L, Kristiansson E, Ahlman H, Nilsson O: Hypoxia stimulates CXCR4 signalling in ileal carcinoids. Endocr Relat Cancer; 2010 Jun;17(2):303-16
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumour hypoxia is associated with increased metastatic potential and resistance to radiotherapy and chemotherapy.
  • Ileal carcinoids are usually metastatic at the time of diagnosis and respond poorly to chemotherapy.
  • The aim of this study was to investigate the extent of hypoxia in ileal carcinoids and the response of tumour cells to induced hypoxia.
  • All hypoxic markers were shown to be highly expressed in localized areas of the tumours irrespective of tumour location or stage.
  • Global gene expression profiling of GOT1 carcinoid cells revealed a marked response to hypoxia.
  • Expression of genes related to epithelial-to-mesenchymal transition and development was altered including increased expression of the C-X-C chemokine receptor type 4 (CXCR4), an important regulator of invasive growth and metastasis formation.
  • High expression of CXCR4 was confirmed by immunohistochemistry in tumour biopsies.
  • Stimulation of GOT1 cells by the CXCR4 ligand, CXCL12 (stromal cell-derived factor 1 (SDF-1)), activated the mitogen-activated protein kinase (MAPK) p42/44 signalling pathway and increased tumour cell migration.
  • Signalling through the CXCL12-CXCR4 axis may contribute to the metastatic potential of ileal carcinoids.
  • Targeting of HIFs and/or the CXCR4 signalling pathway may offer new therapeutic strategies for carcinoid tumour disease.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / metabolism. Carcinoid Tumor / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Ileal Neoplasms / metabolism. Receptors, CXCR4 / metabolism

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20071457.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / CXCR4 protein, human; 0 / Chemokine CXCL12; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Receptors, CXCR4; 0 / Vascular Endothelial Growth Factors; 0 / endothelial PAS domain-containing protein 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


30. Meyers MO, Anthony LB, McCarthy KE, Drouant G, Maloney TJ, Espanan GD, Woltering EA: High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor. South Med J; 2000 Aug;93(8):809-11
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor.
  • We hypothesized that high-dose 111In-pentetreotide could be therapeutic in patients with somatostatin receptor-expressing tumors.
  • Our 35-year-old patient had atypical carcinoid tumor metastatic to cervical, supraclavicular, mediastinal, and mesenteric lymph nodes and to the liver and bone.
  • Chemotherapy had stabilized the disease but with severe gastrointestinal side effects.
  • After a diagnostic 111In-pentetreotide scan, the patient was given eight courses (180 mCi each) of 111In-pentetreotide therapy to selectively target somatostatin receptor-expressing tumor cells.
  • The patient had two additional courses of 111In-pentetreotide therapy (360 mCi each).
  • She died of the disease approximately 18 months after initiation of 111In-pentetreotide therapy.
  • [MeSH-major] Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Carcinoid Tumor / radiotherapy. Carcinoid Tumor / secondary. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Lymphatic Metastasis / radiotherapy. Somatostatin / analogs & derivatives
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Female. Humans. Ifosfamide / administration & dosage. Receptors, Somatostatin / analysis. Receptors, Somatostatin / drug effects

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10963516.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Receptors, Somatostatin; 51110-01-1 / Somatostatin; 6PLQ3CP4P3 / Etoposide; G083B71P98 / pentetreotide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


31. Pectasides D, Glotsos J, Bountouroglou NG, Dadioti PA, Athanassiou AE: Primary carcinoid of the testis with metastases. Case report and review of the literature. J BUON; 2002 Apr-Jun;7(2):153-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoid of the testis with metastases. Case report and review of the literature.
  • Primary carcinoid of the testis is an extremely rare neoplasm, making up 0.23% of all testicular neoplasms.
  • We present a case of a 50-year-old man with a primary testicular carcinoid who developed lymph node and lung metastases 4 months after left inguinal orchidectomy.
  • Our case was not associated with testicular teratoma or carcinoid syndrome.
  • Vigorous efforts were done postoperatively to exclude the possibility of carcinoid tumor metastatic to the testis.
  • Our patient achieved a mixed response (lung metastases: complete response, lymph node metastases: partial response) with combined therapy that included chemotherapy (cisplatin, etoposide, ifosfamide, epirubicin), octreotide and radiotherapy to the metastatic lymph nodes.
  • We herein review the literature and discuss all the possibilities to explain the origin of carcinoid tumors of the testis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577281.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


32. Plöckinger U, Wiedenmann B: [Neuroendocrine tumours of the gastrointestinal tract]. Z Gastroenterol; 2004 Jun;42(6):517-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Neuroendokrine Tumoren des Gastrointestinaltrakts.
  • Abdominal ultrasound (US), computed tomography (CT), magnetic resonance tomography (MRT) and somatostatin receptor scintigraphy (SRS) are used for localisation of the primary tumour and metastasis.
  • For localised tumours surgery is the first line treatment.
  • In metastatic disease symptomatic therapy, biotherapy and chemotherapy are available.
  • Cytoreductive therapy such as embolisation, chemoembolisation, thermo- or cryotherapy, or radio-receptor therapy are additional options.
  • An increased chromogranin-A plasma concentration or 5-hydroxyindoleacetic acid 24-h urinary excretion indicates the neuroendocrine origin of the tumour or the possibility of a carcinoid syndrome, respectively.
  • Surgical therapy prolongs survival but is rarely curative.
  • Biotherapy is effective as symptomatic therapy.
  • Chemotherapy is less effective in midgut tumours compared to foregut tumours.
  • Cytoreductive strategies (chemoembolisation, thermo- or cryotherapy, cytoreductive surgery) and radio-receptor therapy may offer new therapeutic options.
  • However, their definitive value has yet to be defined.
  • [MeSH-major] Endoscopy, Gastrointestinal / methods. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / therapy. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / therapy. Patient Care Management / methods
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy / methods. Diagnosis, Differential. Humans. Palliative Care / methods. Practice Guidelines as Topic. Practice Patterns, Physicians'. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15190448.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 38
  •  go-up   go-down


33. Kunz J, Makek M: [Primary adenocarcinoma of the appendix as differential diagnosis of advanced ovarian carcinoma]. Praxis (Bern 1994); 2006 Aug 16;95(33):1217-25
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Das primäre Adenokarzinom der Appendix als Differentialdiagnose des fortgeschrittenen Ovarialkarzinoms.
  • They are usually carcinoid tumours that must be distinguished from extremely rare adenocarcinomas.
  • Metastatic mucinous adenocarcinomas of the appendix are only reported as case histories.
  • In clinical terms, the tumours usually manifest themselves as acute appendicitis, as ruptured appendicitis, as a tumour in the right lower abdominal quadrant or as a pelvic tumour, which are generally mistaken for an ovarian tumour with the same sonographic image.
  • The pathologist makes the definitive diagnosis.
  • Surgical therapy of the isolated primary appendiceal carcinoma consists of a hemicolectomy--an appendectomy in favourable cases--and, in the case of a metastasised carcinoma, according to the guidelines for an advanced ovarian or colon carcinoma.
  • The effect of chemotherapy is insufficiently documented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939122.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


34. Hamada T, Tanaka M, Hashimoto Y, Yamauchi M, Shigeoka N, Shima H, Nakai K, Suenaga K, Nakayama H: [A case of endocrine cell carcinoma of the ileum: sonographic findings and clinical outcome]. Nihon Shokakibyo Gakkai Zasshi; 2006 Oct;103(10):1139-45
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 56-year-old man, who had been complaining of diarrhea for several months, was admitted for further examination of a hepatic tumor.
  • A needle biopsy of the hepatic tumor suggested metastatic carcinoid tumor.
  • The primary tumor was found in the ileum by extracorporeal sonographic examination and a barium meal study.
  • We performed a partial excision of the ileum, lymph node resection, wedge biopsy of the liver, and catheterization from the right iliac artery to the hepatic artery for intraarterial chemotherapy.
  • [MeSH-major] Carcinoid Tumor / ultrasonography. Ileal Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17023756.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 23
  •  go-up   go-down


35. Hatta R, Nambu Y, Suzuki S, Tachi Y, Oikawa T, Nakagawa K, Tuchihara K, Tobe T, Osanai K, Toga H, Takahashi K, Ohya N: [A case of atypical pulmonary carcinoid accompanying skin metastasis]. Nihon Kokyuki Gakkai Zasshi; 2004 Apr;42(4):357-61
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of atypical pulmonary carcinoid accompanying skin metastasis].
  • She began complaining of headache 2 years postoperatively, and around the same time, she noticed a painful skin tumor.
  • The skin tumor was diagnosed by skin biopsy as an atypical metastatic carcinoid tumor.
  • Pulmonary, skin and bone biopsy samples exhibited the same pathological findings as those of the atypical pulmonary carcinoid tumor.
  • She did not show any carcinoid symptoms.
  • EP therapy (etoposide + carboplatin) and CAV therapy (cyclophosphamide + doxorubicin + vincristin) were administered, but there was no clinical response.
  • The patient is currently doing well without chemotherapy and is being followed by the Outpatient Department.
  • [MeSH-major] Carcinoid Tumor / pathology. Carcinoid Tumor / secondary. Lung Neoplasms / pathology. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15114855.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


36. Pansini GC, Lanzara S, Feo CV, Zamboni P, Liboni A, Ambrosio MR, Marzola A, Feggi L: [Malignancy: treatment and prognosis of gastrointestinal and pancreatic endocrine neoplasia: retrospective study of a series of 16 cases]. Ann Ital Chir; 2001 Jul-Aug;72(4):413-21; discussion 422
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignancy: treatment and prognosis of gastrointestinal and pancreatic endocrine neoplasia: retrospective study of a series of 16 cases].
  • Of these patients we reviewed preoperative symptoms, diagnostic techniques (ultrasound, CT, MRI, radiolabelled octreotide scintigraphy, angiography, immunohistochemical study), treatment (surgical operation, neoadjuvant and adjuvant chemotherapy, and radiometabolic therapy) and survival.
  • Nine patients (56%) had a carcinoid tumour, three (19%) an unspecified endocrine tumour, and four (25%) an endocrine tumour associated with a non-endocrine neoplasm.
  • Only five patients (31%) had a preoperative diagnosis of endocrine tumour.
  • Eight patients (50%) had metastatic disease at the time of the operation.
  • Of eight patients with metastatic disease, six (75%) died after a mean of 20.5 months (3-60 months) and two (25%) are still alive with the disease after 3 and 6 months, respectively.
  • Furthermore, survival of patients with metastatic disease seems to be longer as compared to other gastrointestinal tract malignancies.
  • The optimal treatment for ETGIP is a multimodal approach with surgical operation, chemoradiation, radiometabolic, and genetic therapies.
  • [MeSH-major] Endocrine Gland Neoplasms / therapy. Gastrointestinal Neoplasms / therapy. Pancreatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11865693.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


37. Correale P, Sciandivasci A, Intrivici C, Pascucci A, Del Vecchio MT, Marsili S, Savelli V, Voltolini L, Di Bisceglie M, Guarnieri A, Gotti G, Francini G: Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation. Br J Cancer; 2007 May 7;96(9):1343-7
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation.
  • We report the results of a phase II trial in patients with metastatic endocrine tumours from different sites, which aimed to evaluate the anti-tumour activity and toxicity of a cisplatinum and etoposide regimen administered in combination with the somatostatin agonist lanreotide given in slow release formulation.
  • Between January 1999 and November 2003, 27 patients with histological diagnoses of endocrine tumours with different degrees of differentiation, excluding well differentiated carcinoid neoplasms, received intravenous (i.v.) administration of cisplatinum (30 mg m(-2)) and etoposide (100 mg m(-2)) on days 1-3 and intramuscular administration of 60 mg lanreotide on day 1, in a 21-day cycle.
  • The treatment was very well tolerated as no grade 4 toxicity was observed.
  • The average time to progression and to survival were 9 and 24 months respectively.
  • These results suggest that this chemo-hormone therapy regimen is well tolerated and active in patients with non-well differentiated endocrine tumours.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endocrine Gland Neoplasms / drug therapy

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(8):1351-5 [10604732.001]
  • [Cites] Crit Care. 2006;10(4):218 [16834764.001]
  • [Cites] Cancer. 2000 Jun 25;90(3):148-61 [10896328.001]
  • [Cites] Q J Nucl Med. 2000 Mar;44(1):96-101 [10932606.001]
  • [Cites] Crit Rev Oncol Hematol. 2001 Jan;37(1):47-51 [11164718.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14(1):38-45 [11790979.001]
  • [Cites] Am J Clin Pathol. 2001 Jun;115 Suppl:S5-16 [11993690.001]
  • [Cites] Am J Clin Pathol. 2001 Jun;115 Suppl:S79-93 [11993693.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2003;(212):28-36 [12841325.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2689-96 [12860945.001]
  • [Cites] Mol Endocrinol. 2003 Sep;17(9):1726-37 [12775765.001]
  • [Cites] Expert Rev Anticancer Ther. 2003 Oct;3(5):631-42 [14599087.001]
  • [Cites] J Urol. 2004 Jan;171(1):443-4 [14665951.001]
  • [Cites] Cell Prolif. 2004 Feb;37(1):89-96 [14871239.001]
  • [Cites] N Engl J Med. 1986 Sep 11;315(11):663-6 [2427948.001]
  • [Cites] Am J Med. 1986 Dec 22;81(6B):14-22 [2879446.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1502-22 [2443618.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;58(2):95-121 [2575822.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):227-32 [1712661.001]
  • [Cites] Ann N Y Acad Sci. 1994 Sep 15;733:1-17 [7978856.001]
  • [Cites] Ann Oncol. 1995 Jan;6(1):77-9 [7710986.001]
  • [Cites] J Endocrinol Invest. 1997 Jun;20(6):348-67 [9294784.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):372-8 [9669822.001]
  • [Cites] Carcinogenesis. 2004 Nov;25(11):2075-81 [15205362.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2004 Dec;18(4):607-22 [15533778.001]
  • [Cites] Clin Sci (Lond). 2005 Jan;108(1):1-11 [15384949.001]
  • [Cites] BMC Cell Biol. 2005;6(1):2 [15656904.001]
  • [Cites] World J Surg. 2005 Mar;29(3):293-6 [15706439.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1374-80 [15939719.001]
  • [Cites] Prostate. 2006 Feb 15;66(3):227-34 [16173029.001]
  • [Cites] Mol Endocrinol. 2006 Feb;20(2):426-36 [16223973.001]
  • [Cites] FEBS Lett. 2006 Apr 17;580(9):2258-64 [16579994.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3548-54 [16877720.001]
  • [Cites] Anticancer Drugs. 2006 Jul;17(6):601-8 [16917205.001]
  • [Cites] Ital J Gastroenterol Hepatol. 1999 Oct;31 Suppl 2:S202-6 [10604131.001]
  • (PMID = 17437022.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2360193
  •  go-up   go-down


38. Arnold R, Wied M, Behr TH: Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract. Expert Opin Pharmacother; 2002 Jun;3(6):643-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract.
  • Somatostatin and its long-acting analogues have been introduced for the treatment of endocrine tumours of the gastrointestinal tract as they have been shown to effectively control symptoms resulting from excessive hormone release in patients with carcinoid, Verner-Morrison and glucagonoma syndromes.
  • The antiproliferative potency of somatostatin and its analogues in vitro and in experimental tumour models prompted a number of studies in patients with metastatic endocrine tumours that are generally unresponsive to conventional chemotherapeutic protocols.
  • Stabilisation of tumour growth lasting for months to a few years was the most favourable result, occurring in 30 - 70% of patients.
  • Radioligand therapy based on 111Indium, 90Yttrium and 177Lutetium coupled to somatostatin analogues via bifunctional chelators is currently under investigation with promising data concerning long-lasting control of symptoms and tumour growth from Phase I trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Neoplasms / drug therapy. Neoplasms, Glandular and Epithelial / drug therapy. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use
  • [MeSH-minor] Animals. Clinical Trials as Topic. Drug Therapy, Combination. Humans. Interferon-alpha / therapeutic use. Octreotide / therapeutic use. Peptides, Cyclic / therapeutic use. Radioisotopes / therapeutic use. Receptors, Somatostatin / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Expert Opin Pharmacother. 2002 Jul;3(7):1029
  • (PMID = 12472080.001).
  • [ISSN] 1465-6566
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Peptides, Cyclic; 0 / Radioisotopes; 0 / Receptors, Somatostatin; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin; RWM8CCW8GP / Octreotide
  • [Number-of-references] 134
  •  go-up   go-down


39. Appetecchia M, Baldelli R: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res; 2010;29:19
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.
  • Gastroenteropancreatic neuroendocrine tumours (GEP NETs) are rare tumours that present many clinical features.They secrete peptides and neuroamines that cause distinct clinical syndromes, including carcinoid syndrome.
  • However, many are clinically silent until late presentation with mass effects.In 2000 the WHO developed a new classification which gives a better description of the characteristics and biological behaviour of the tumour.Surgical resection is the treatment of first choice for a patient with a GEP NET.
  • In metastatic disease multiple therapeutic approaches are possible.
  • In these cases the goal is to improve quality of life and to extent survival.GEP NETs express somatostatin receptors (SSTRs), which are bound by somatostatin (SST) or its synthetic analogues, although the subtypes and number of SSTRs expressed is very variable.Somatostatin analogues are used frequently to control hormone-related symptoms while their anti-neoplastic activity, even if it has not been widely studied and the regarding data are discordant, seems to result prevalently in tumour stabilisation.A few patients who fail to respond or cease to respond to standard SST analogues treatment seem to have a response to higher doses of these drugs.The use of higher doses of somatostatin analogues or the development of new subtype selective agonists and chimaeric somatostatin analogues, or pan-somatostatin will probably improve the clinical management of these patients.This review provides an update on the use of somatostatin analogues in the management of GEP NETs and discusses novel clinical strategies based on SSTR 2 gene transfer therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Neoplasms / drug therapy. Neuroendocrine Tumors / drug therapy. Pancreatic Neoplasms / drug therapy. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use
  • [MeSH-minor] Animals. Genetic Therapy. Humans. Interferons / administration & dosage. Receptors, Somatostatin / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Recent Results Cancer Res. 1996;142:193-207 [8893342.001]
  • [Cites] Invest New Drugs. 1997;15(1):77-86 [9195291.001]
  • [Cites] Ann Oncol. 1997 Oct;8(10):1041-4 [9402179.001]
  • [Cites] Acta Oncol. 1997;36(6):607-14 [9408151.001]
  • [Cites] Proc Soc Exp Biol Med. 1998 Feb;217(2):143-52 [9452137.001]
  • [Cites] Gut. 1998 Jun;42(6):792-4 [9691916.001]
  • [Cites] Clin Cancer Res. 1997 Feb;3(2):265-72 [9815682.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Feb 16;268(2):567-71 [10679244.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):770-6 [10679645.001]
  • [Cites] Nucl Med Biol. 1999 Nov;26(8):877-82 [10708300.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7862-9 [10713101.001]
  • [Cites] Aliment Pharmacol Ther. 2000 May;14(5):557-60 [10792118.001]
  • [Cites] Surg Today. 2000;30(6):541-3 [10883468.001]
  • [Cites] Curr Opin Oncol. 2000 Jul;12(4):368-77 [10888424.001]
  • [Cites] Curr Med Chem. 2000 Sep;7(9):971-94 [10911025.001]
  • [Cites] N Engl J Med. 2000 Aug 24;343(8):551-4 [10954763.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3276-81 [11095353.001]
  • [Cites] Chemotherapy. 2001;47 Suppl 2:1-29 [11275699.001]
  • [Cites] Chemotherapy. 2001;47 Suppl 2:30-9 [11275700.001]
  • [Cites] Eur J Cancer. 2001 May;37(8):1014-9 [11334727.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):941-5 [11521799.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S105-9 [11762334.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):331-43 [11900219.001]
  • [Cites] Eur J Endocrinol. 2002 May;146(5):707-16 [11980628.001]
  • [Cites] Virchows Arch. 2002 May;440(5):461-75 [12021920.001]
  • [Cites] Biopolymers. 2002;66(3):161-83 [12385036.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6124-31 [12414637.001]
  • [Cites] Trends Endocrinol Metab. 2002 Dec;13(10):451-7 [12431842.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 May;30(5):781-93 [12707737.001]
  • [Cites] Br J Surg. 2003 Jun;90(6):687-93 [12808615.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 Jun;15(6):705-7 [12840685.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2689-96 [12860945.001]
  • [Cites] J Pharm Pharmacol. 2004 Apr;56(4):471-6 [15099442.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):966-73 [15151956.001]
  • [Cites] Eur J Endocrinol. 2004 Jul;151(1):15-27 [15248818.001]
  • [Cites] Eur J Endocrinol. 2004 Jul;151(1):107-12 [15248829.001]
  • [Cites] Cancer Chemother Biol Response Modif. 2003;21:535-46 [15338762.001]
  • [Cites] Trends Endocrinol Metab. 2004 Sep;15(7):300-10 [15350601.001]
  • [Cites] Scand J Gastroenterol. 2004 Jul;39(7):621-8 [15370681.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:23-7 [15477712.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:51-6 [15477718.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:57-61 [15477719.001]
  • [Cites] Life Sci. 1982 Sep 13;31(11):1133-40 [6128648.001]
  • [Cites] Acta Endocrinol (Copenh). 1985 May;109(1):108-14 [2860768.001]
  • [Cites] Clin Endocrinol (Oxf). 1986 Nov;25(5):555-60 [2887309.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1502-22 [2443618.001]
  • [Cites] Clin Endocrinol (Oxf). 1988 Feb;28(2):181-5 [2844445.001]
  • [Cites] Cancer Res. 1988 Dec 15;48(24 Pt 1):6977-85 [2903792.001]
  • [Cites] Horm Res. 1988;29(5-6):211-3 [2851522.001]
  • [Cites] Metabolism. 1990 Sep;39(9 Suppl 2):152-5 [2169572.001]
  • [Cites] Br J Cancer. 1990 Oct;62(4):627-30 [1977468.001]
  • [Cites] J Histochem Cytochem. 1969 May;17(5):303-13 [4143745.001]
  • [Cites] Endocr Rev. 1991 Nov;12(4):450-82 [1684746.001]
  • [Cites] J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):27-35 [1356016.001]
  • [Cites] Eur J Cancer. 1992;28A(10):1647-50 [1382492.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):244-8 [8389666.001]
  • [Cites] Acta Oncol. 1993;32(2):217-23 [7686764.001]
  • [Cites] Digestion. 1993;54 Suppl 1:72-5 [8359572.001]
  • [Cites] World J Surg. 1993 Jul-Aug;17(4):444-7 [8395748.001]
  • [Cites] J Intern Med. 1994 Mar;235(3):245-8 [8120520.001]
  • [Cites] Pharmacol Ther. 1993 Nov;60(2):245-64 [7912834.001]
  • [Cites] Medicine (Baltimore). 1996 Mar;75(2):53-63 [8606627.001]
  • [Cites] Cancer Res. 1996 Apr 15;56(8):1823-7 [8620499.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):402-8 [8625251.001]
  • [Cites] Gut. 1996 Mar;38(3):430-8 [8675099.001]
  • [Cites] J Nucl Med. 1996 Sep;37(9):1519-21 [8790206.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):858-68 [10080850.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):600-6 [10080605.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1381-7 [10235222.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Mar;18(1):13-22 [10374671.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 2:S23-9 [10399029.001]
  • [Cites] Ital J Gastroenterol Hepatol. 1999 May;31(4):308-12 [10425577.001]
  • [Cites] Digestion. 1999 Sep-Oct;60(5):469-76 [10473972.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S [15653647.001]
  • [Cites] Neuroendocrinology. 2004;80(4):244-51 [15627802.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2005 Jun;19(2):265-76 [15763700.001]
  • [Cites] World J Gastroenterol. 2005 Apr 7;11(13):2041-4 [15801004.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2754-62 [15837990.001]
  • [Cites] Eur J Endocrinol. 2005 May;152(5):757-67 [15879362.001]
  • [Cites] Gut. 2005 Jun;54 Suppl 4:iv1-16 [15888809.001]
  • [Cites] Neuroendocrinology. 2004;80(6):394-424 [15838182.001]
  • [Cites] Hum Gene Ther. 2005 Oct;16(10):1175-93 [16218779.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Aug;3(8):761-71 [16234004.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Dec;289(6):E1044-50 [16046458.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):461-6 [16364959.001]
  • [Cites] Horm Res. 2006;65(3):120-5 [16479142.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Mar;25(1):135-9 [16761630.001]
  • [Cites] Anticancer Drugs. 2006 Jul;17(6):601-8 [16917205.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Nov;132(11):699-708 [16835748.001]
  • [Cites] Pituitary. 2006;9(3):243-8 [17001462.001]
  • [Cites] Eur J Endocrinol. 2006 Dec;155(6):849-57 [17132755.001]
  • [Cites] Cell Death Differ. 2007 Feb;14(2):197-208 [16645635.001]
  • [Cites] Anticancer Drugs. 2007 Mar;18(3):341-8 [17264768.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):111-29 [17382268.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):145-62 [17382270.001]
  • [Cites] Eur J Endocrinol. 2007 Apr;156 Suppl 1:S23-8 [17413184.001]
  • [Cites] Endocrinology. 2007 May;148(5):2095-105 [17272399.001]
  • [Cites] World J Gastroenterol. 2007 Jun 21;13(23):3164-70 [17589893.001]
  • [Cites] Expert Opin Emerg Drugs. 2007 May;12(2):253-70 [17604500.001]
  • [Cites] Regul Pept. 2007 Oct 4;143(1-3):109-17 [17531331.001]
  • [Cites] Cell Signal. 2007 Nov;19(11):2304-16 [17706924.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):61-72 [18177818.001]
  • [Cites] J Gastrointest Surg. 2008 Feb;12(2):382-93 [17510774.001]
  • [Cites] Am J Gastroenterol. 2008 Feb;103(2):475-83; quiz 484 [18028508.001]
  • [Cites] Mol Cell Endocrinol. 2008 May 14;286(1-2):238-50 [18037561.001]
  • [Cites] Mol Cell Endocrinol. 2008 May 14;286(1-2):230-7 [18359151.001]
  • [Cites] Cancer. 2008 Jul 15;113(2):256-65 [18506737.001]
  • [Cites] Endocrine. 2009 Apr;35(2):143-6 [19184565.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4656-63 [19704057.001]
  • [Cites] Pancreas. 2009 Oct;38(7):811-4 [19657309.001]
  • [Cites] Endocr Relat Cancer. 2009 Dec;16(4):1329-38 [19620247.001]
  • (PMID = 20196864.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 51110-01-1 / Somatostatin; 9008-11-1 / Interferons
  • [Number-of-references] 114
  • [Other-IDs] NLM/ PMC2845555
  •  go-up   go-down






Advertisement